Protein / target
Bcl-2-like protein 2
Protein at a glance
Biological role
Disordered domain specific binding
Strongest disease association
Neurodegenerative Diseases
Therapeutic position
Established drug target
Derived from structured UniProt, Open Targets and literature data on this page.
Protein profile
Canonical identity and biological annotation from UniProt.
Function overview
Promotes cell survival.
View complete UniProt function annotationHide complete annotation
Promotes cell survival. Blocks dexamethasone-induced apoptosis. Mediates survival of postmitotic Sertoli cells by suppressing death-promoting activity of BAX
Subcellular location
Domains and Gene Ontology detail (14)Hide
Gene Ontology
- CBcl-2 family protein complex
- Ccytosol
- Cmitochondrial outer membrane
- Cmitochondrion
- Fchannel activity
- Fdisordered domain specific binding
- Fidentical protein binding
- Pextrinsic apoptotic signaling pathway in absence of ligand
- Pintrinsic apoptotic signaling pathway in response to DNA damage
- Pnegative regulation of apoptotic process
- Ppositive regulation of apoptotic process
- Pregulation of apoptotic process
Biological roles
What this protein does, drawn together from its UniProt function, Gene Ontology terms and Reactome pathways.
View supporting evidenceHide supporting evidence
Cell proliferation & survival
- ·Promotes cell survival. Blocks dexamethasone-induced apoptosis. Mediates survival of pos…
Apoptosis & cell death
- ·negative regulation of apoptotic process
- ·positive regulation of apoptotic process
- ·regulation of apoptotic process
Concepts derived from UniProt GO Reactome — each badge above shows which sources supported that role.
Interaction neighbourhood
Proteins with the strongest functional or physical association. Node size and line weight reflect STRING confidence; hover or select a partner to inspect one association.
Functional and physical associations from STRING v12.0. Only associations with this protein are drawn — partner-to-partner links are not part of this evidence.
Drugs targeting this protein
How approved and investigational drugs engage this protein — mechanism and action type, direct vs complex targeting, and how broadly each acts across other targets. A drug-first view (the section above groups the approved ones disease-first); direct binders with few recorded targets are listed first.
Apoptosis regulator Bcl-W inhibitor
ChEMBL mechanism, action type, target identity and approved indications. Open Targets clinical status.
Translational evidence
Why this target matters therapeutically, strongest evidence first. Disease associations are gene-level (via the gene that encodes this protein) and open into the full confidence synthesis; the development universe, tractability and safety annotations are target-level, from Open Targets.
Strongest disease associations · via encoding gene BCL2L2
Gene-level evidence surfaced through the gene BCL2L2 that encodes this protein — not a direct protein–disease relationship. Ranked by Forefront's causal-directness weighting, so genetically- and clinically-evidenced diseases lead over ones that merely share the literature.
View evidence synthesis (5)Hide
This ranking differs from Open Targets' own: re-weighting moves genetically-evidenced diseases above more heavily co-mentioned ones. The evidence agreement range shows how closely the independent evidence families agree — it is not a statistical confidence interval, and nothing here is fitted to outcome data. Derived from Open Targets evidence types under Forefront weighting; the per-type scores above show the calculation.
Show all associationsHide all associations
Drug development
3 compounds recorded · 1 approved · 2 in clinical development
View all recorded compounds (3)Hide
Open Targets known-drugs universe. Drug name and highest clinical stage only — the disease relationship is NOT read from this slice (it carries trial-context noise); approved indications come from the canonical graph above.
Tractability
Small molecules — Strong
Antibodies — Emerging
Protein degraders — Emerging
View underlying tractability evidence (7)Hide
Raw Open Targets tractability assessment buckets, by modality.
Clinical trials
Trials of drugs that target this protein — reached indirectly through those drugs, so a trial listed here studies the drug, not the protein. Ranked by active status, then clinical phase and recency, and spread across the targeting drugs.
View all trials (20)Hide
ClinicalTrials.gov via the drug-target graph.